ALPMY Stock UPDATES Astellas Pharma Inc (ALPMY) 14.4850 09/02/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2014 at 11:09 AM

Astellas Pharma Inc (ALPMY) 14.4850 $ALPMY

Astellas-Basilea's Isavuconazole Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:30PM CDT
Astellas Pharma, Inc. (ALPMY) and Basilea's isavuconazole has been accepted for review in the EU for the treatment of invasive aspergillosis and mucormycosis.

AVEO Pharmaceuticals Posts Narrower-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:30AM CDT
AVEO Pharmaceuticals reported a second-quarter 2014 loss of 35 cents per share.

Medivation Jumps on Q2 Earnings Beat, Outlook Encourages - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:10AM CDT
Medivation Inc. (MDVN) posted earnings of 60 cents per share.

Astellas Up on Pipeline Update, Oncology in Focus (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 3:07PM CDT
Astellas Pharma, Inc. (ALPMY) provided a comprehensive overview of its initiatives towards innovation, research and development and its corporate strategy.

Astellas' Isavuconazole Gets QIDP for Invasive Candidiasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 4:50PM CDT
Astellas Pharma, Inc.'s (ALPMY) isavuconazole received Qualified Infectious Disease Product (QIDP) designation from the FDA for treating invasive candidiasis.

Astellas Up on Pipeline Update, Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 2:03PM CDT
Astellas Pharma, Inc.'s (ALPMY) shares gained 2.5% following the company's update on its pipeline and corporate strategy late last week.

Astellas Seeks FDA Nod for Fungal Infection Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 4:30PM CDT
Astellas Pharma, Inc. (ALPMY) has filed an NDA with the FDA for isavuconazole for the treatment of invasive aspergillosis and mucormycosis.

ARIAD Candidate in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:10PM CDT
ARIAD started phase II pivotal study on AP26113 for non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer's Xalkori (crizotinib).

AstraZeneca's Forxiga Approved in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 3:45PM CDT
AstraZeneca announced that its type II diabetes drug, Forxiga, has been approved by the Japanese Ministry of Health, Labour and Welfare.

Japan Approves Medivation/Astellas' Xtandi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 12:50PM CDT
Prostate cancer treatment, Xtandi, which is already approved in more than 35 countries is now approved in Japan.

AVEO Regains AV-203 Rights from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 5:10PM CDT
AVEO Oncology (AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).

Medivation, Inc: Fast Growing Drugs That May Become Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
Blockbuster status -- the gold medal term awarded to therapies racking up sales of more than $1 billion per year -- is the Holy Grail for drug developers. Arguably, it's the chance to discover blockbusters that fuels industry R&D spend and...

Medivation-Astellas Seek Xtandi Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 3:20PM CDT
The companies are looking to get Xtandi approved for the chemo-naive patient population.

AVEO Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:10AM CDT
AVEO Pharmaceuticals reported a fourth quarter 2013 loss of 32 cents per share.

Was Medivation's Quarter a Disaster?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 03, 5:30PM CST
Medivation's sell-off last week reflects investor disappointment in guidance for sales of Xtandi, a prostate cancer drug prescribed to patients who fail to respond to chemotherapy. Sales of Xtandi jumped double digit percentages...

Medivation Swings to Earnings in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:30AM CST
Xtandi's approval in the pre-chemo setting would boost sales significantly.

Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.

Primco Files Preliminary Form 14c to Increase Authorized Shares
PR Newswire - Tue Feb 18, 11:30PM CST
Primco Management Inc. (OTCQB: PMCM), a fully integrated multi-media entertainment and real estate development company today announced that the Company has filed Form 14c, as required by the Securities and Exchange Commission, informing shareholders of an increase in the authorized to 25 billion common shares as a reserve requirement for possible future conversion issuances, in accordance with contractual obligations to convertible debt holders based on the recent low stock price of $0.0001. The increase will further allow Primco to have sufficient shares available for equity funding, and/or for potential acquisitions which the Board of Directors may determine is in the best interest of the shareholders.

AVEO/Astellas Terminate Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 3:30PM CST
AVEO Pharma and Astellas announced their decision to terminate their agreement for the development and commercialization of tivozanib.

Vical Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 11:10AM CST
Vical's fourth quarter loss narrows

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Medicare Limits and Long-Term Care Planning Tips

Grappling with Medicare's Gaps Most folks hear Medicare and feel a sigh of relief—thinking it's a catch-all net for healthcare in your golden years. But hold on, when it comes to long-term care, Medicare's got more holes than Swiss cheese. Cindy Couyoumjian from Cinergy Financial lays it out pretty clear: Medicare doesn't cover what it calls 'custodial care'—you know,...

Got Electric Expands to Coeburn, Strengthening Infrastructure

You ever get tired of hearing the same old corporate spiel? Well, here's something real—Got Electric just opened a new office in Coeburn, Virginia, and it ain't just another pin on the map. It’s a move with some teeth, beefing up their ability to handle the electrical needs of Virginia, Tennessee, and North Carolina. A strategic play that’s got some serious regional...

Violet PR's Big Wins Hint at Industry Strategies

A Shining Night in Morristown Picture Violet PR's team on top of the world, right there in Morristown, getting the accolades every agency dreams of—five awards from PRSA-NJ. It's not just an ego trip, either. This is about setting a high bar in the world of strategic communications, and they're flaunting their ability to drive growth and innovation in the economic...

Paolo Moretti: New CEO Steering RINA's Dynamic Course

Leadership Shift in the Heart of RINA Today's news is a hefty dose of strategic sea change over at RINA S.p.A., where Paolo Moretti's been handed the reins as the new Group Chief Executive Officer. Now, if you haven't been following, RINA's been riding a serious wave—revenues have more than doubled in a neat five-year streak, claiming over a billion euros. So, what we...

Home Insurance Gaps: Risky Assumptions Uncovered

Unseen Threats to Homeownership Safety Liability gaps in insurance are like those stubborn stains on the carpet you keep missing—nearly invisible until you're flat on your face. In Alpharetta and Fulton County, homes aren't as secure from financial pitfalls as their charming façades suggest. So, what's the danger that folks are glossing over here? Hidden Dangers of...

AZ Health Workers Step Up for Community Wellness

Health Screenings: A Step Before the Hospital Sometimes it's the basics, like a plain old health screening, that can shift the tides from crisis to care. That's exactly where AZ Blue Health Choice and Zeihan ProHealth come into the picture, aiming to pin those health concerns before they spiral out of control. For your average Arizonan who finds healthcare as elusive as a...

FRP Moto Unveils M3 Mini: High-Tech Wheelie, 55 MPH Speed

Who knew that mini bikes could pack such a punch? Enter the M3 from the folks at FRP Moto. This isn't just another two-wheeler for the kiddie circuit. Nope, this one's got the juice to make even seasoned riders do a double take. We're talking electric power, a top speed of 55 mph, and some snazzy wheelie modes. A Look Under the Hood Get this – the M3 isn’t your...

Cowfest 2026 Delighted by Frederick's Flying Cows

Moo-ving Towards a New Record Alright, listen up. This fall, there's a bovine spectacle coming to Maryland that's more than just a trip down to the fairgrounds—it's Cowfest 2026, baby! Now, if you're scratching your head thinking this is just another seasonal shindig, you're underestimating what's mooing across Frederick County. The Flying Cows are ready to take the...

3Srobotics Breaks Ground with North American Debut

3Srobotics Steps Into the Big League The sweltering buzz of FABTECH 2026 in Las Vegas signals more than just another industry tradeshow; it's the stage upon which 3Srobotics made its North American debut. In a span shorter than it takes most companies to get serious about their business cards, 3Srobotics has already nailed three funding rounds, snagging tens of millions...

Csquare Investors Face Tough Questions Amid Probe

Csquare's Shaky Claims and Market Consequences When a company flashes big numbers like $356 million to showcase its financial health, it sure gets the ticker NYSE:CSQR buzzing. But here's the rub—over half of that is locked up tighter than a drum, off-limits for general use. You gotta appreciate the irony, right? Someone's turned up a rock and there it is, a mess of...